Oramed Pharmaceuticals Inc. Announces New Rights Distribution
In a significant move for its shareholders, Oramed Pharmaceuticals Inc. has recently declared a dividend of common stock purchase rights, also known as "Rights." This decision was made unanimously by the Board of Directors as part of the company’s commitment to enhancing shareholder value and ensuring fair treatment during potential takeover attempts.
Understanding the Rights Agreement
The newly established Rights Agreement, adopted to safeguard shareholder interests, allows stockholders to receive one Right for each outstanding share of common stock. This strategic plan is designed to prevent hostile takeovers and ensure that any prospective acquirers negotiate in good faith with all shareholders, thus fostering an environment of fairness and transparency.
Exercise of Rights
Initially, each Right will grant stockholders the ability to purchase one share of Oramed's Common Stock at a predetermined price. This provision becomes active ten business days after an individual or group acquires 15% or more of the company’s common stock, or makes an announcement regarding a tender offer. On certain conditions, the Board of Directors holds the authority to redeem these Rights at a specified per-Right price, ensuring control over extraordinary ownership changes.
Implications of Triggering Events
If the Rights become exercisable, significant changes will occur regarding how they influence stockholder purchases. Each Right, when activated, will entitle holders to buy shares at twice the exercise price, broadening the value of their investment. However, Rights held by the triggering person will be void, ensuring that the balance of the rights is upheld fairly among remaining shareholders.
Key Dates for Stockholders
Shareholders should note that the distribution will take effect shortly, with crucial dates marking when stockholders must be recorded as active to qualify. The Rights will be distributed soon, and while they will expire three years after their adoption, it's important to highlight that this action has no immediate tax implications for participating stockholders.
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) continues to innovate in the pharmaceutical landscape, focusing on pioneering oral delivery systems for medications traditionally administered via injections. Their technology aims not only to enhance absorption but also to maintain the integrity of biopharmaceuticals. This commitment to advancing medicine presents a brighter future for patients and shareholders alike.
Company Contact
For further inquiries, please reach out to Oramed at +1-844-9-ORAMED or via email at ir@oramed.com.
Frequently Asked Questions
What is the purpose of the Rights Agreement?
The Rights Agreement aims to protect shareholder interests against hostile takeovers by allowing stockholders to purchase additional shares under fair terms.
How does the exercise of Rights work?
Stockholders can initially exercise their Rights to buy shares at a set purchase price after certain conditions are met, ensuring they benefit from their investments.
When will the Rights become exercisable?
The Rights will become exercisable ten business days after a person or group acquires 15% or more of the outstanding Common Stock or announces a tender offer for that amount.
Are the Rights taxable for shareholders?
No, the Rights distribution is not taxable to stockholders upon issuance.
How does Oramed's technology impact the market?
Oramed’s innovative oral delivery solutions position the company as a leader in making medications more accessible, influencing how patients approach treatment.
